Amsterdam Rheumatology and Immunology Center, VU University Medical Centre, PO Box 7057, Amsterdam, 1007 MB, Netherlands.
Department of Clinical Epidemiology and Biostatistics, VU University Medical Center, PO Box 7057, Amsterdam, 1007 MB, Netherlands.
Nat Rev Rheumatol. 2015 Dec;11(12):705-12. doi: 10.1038/nrrheum.2015.116. Epub 2015 Sep 1.
Patient-reported outcomes (PROs) are abundant in rheumatology and their numbers continue to increase. But which of the available measures are most important? Core outcome sets-including groups of domains and instruments for measuring them-have been defined for many rheumatic diseases, with the aim that all these outcomes should be measured in every clinical trial. The subgroup of PROs included in these core sets is, therefore, undoubtedly important. This Review summarizes the PROs included in core outcome sets developed for use in clinical trials across a wide range of rheumatic diseases. Three PROs are commonly utilized across the majority of rheumatic conditions: pain, physical functioning and the patient global assessment of disease activity. However, additional research is needed to fully understand the role of the patient global assessment of disease activity, to distinguish specific domains within the broad concept of health-related quality of life, and to work towards consensus on the choice between generic and disease-specific instruments in various contexts.
患者报告结局(PROs)在风湿病学中大量存在,而且数量还在不断增加。但是,哪些可用的指标最重要呢?核心结局集——包括用于测量这些结局的一系列领域和工具——已经为许多风湿病定义,目的是在每一项临床试验中都应该测量这些结局。因此,这些核心集中包含的患者报告结局亚组无疑是很重要的。这篇综述总结了用于广泛的风湿病临床试验的核心结局集中包含的患者报告结局。三个 PROs 在大多数风湿病中都得到了广泛应用:疼痛、身体功能和患者对疾病活动的总体评估。然而,需要进一步的研究来充分了解患者对疾病活动的总体评估的作用,区分健康相关生活质量这一广泛概念中的特定领域,并在各种情况下就通用和疾病特异性工具的选择达成共识。